Compare ARBB & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBB | XBIO |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 2 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 7.5M |
| IPO Year | 2022 | N/A |
| Metric | ARBB | XBIO |
|---|---|---|
| Price | $4.47 | $3.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 25.8K |
| Earning Date | 04-26-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | $24.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.90 |
| 52 Week High | $13.89 | $13.93 |
| Indicator | ARBB | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 63.53 |
| Support Level | $3.92 | $2.64 |
| Resistance Level | $5.25 | $3.60 |
| Average True Range (ATR) | 0.34 | 0.26 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 11.45 | 74.42 |
ARB IOT Group Ltd is a provider of complete solutions to the clients for the integration of Internet of Things (IoT) systems and devices from designing to project deployment. The company offers a wide range of IoT systems as well as provides customers with a substantial range of services such as system integration and system support services. It delivers solutions like designing, installation, testing and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company operates in two reportable segments: (i) the provision of hardware and software of IoT solutions and (ii) Investment holding and others. The majority of revenue is generated from the IoT solutions segment.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.